Phase III ELSPIRE Trial Results Published in HEPATOLOGY Demonstrates Elafibranor Achieves ALP Normalization in More Than 85% of Patients with Primary Biliary Cholangitis
November 05, 2026
November 05, 2026
ALEXANDRIA, Virginia, Nov. 5 [Category: Medical] -- The American Association for the Study of Liver Diseases posted the following news:
* * *
Phase III ELSPIRE Trial Results Published in HEPATOLOGY Demonstrates Elafibranor Achieves ALP Normalization in More Than 85% of Patients with Primary Biliary Cholangitis
*
Elafibranor significantly improved key markers of disease activity compared with placebo, supporting ALP normalization as an achievabl . . .
* * *
Phase III ELSPIRE Trial Results Published in HEPATOLOGY Demonstrates Elafibranor Achieves ALP Normalization in More Than 85% of Patients with Primary Biliary Cholangitis
*
Elafibranor significantly improved key markers of disease activity compared with placebo, supporting ALP normalization as an achievabl . . .
